請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23442
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李正? | |
dc.contributor.author | Ling-Yu Chang | en |
dc.contributor.author | 張玲瑜 | zh_TW |
dc.date.accessioned | 2021-06-08T05:01:42Z | - |
dc.date.copyright | 2011-10-05 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-19 | |
dc.identifier.citation | 1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-7.
2. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83(9):1032-45. 3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12. 4. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66(5):987-94. 5. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67(5 Suppl):61-70. 6. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010;68(5):959-63. 7. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41(3):318-20. 8. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42(5):841-7. 9. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-61. 10. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433-41. 11. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26(24):4037-8. 12. Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2010;14(3):271-84. 13. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69(5):281-6. 14. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65(3):415-23. 15. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010;28(4):365-83. 16. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-7. 17. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66(4):625-31. 18. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18(12):2015-9. 19. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134(6):620-3. 20. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90(3):1897-9. 21. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24(6):945-52. 22. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008;112(7):2709-12. 23. McLeod NM, Patel V, Kusanale A, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg 2010. 24. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104(4):473-7. 25. Marx RE. Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):107-19. 26. Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck 2010. 27. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):96-106. 28. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110(1):46-53. 29. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009;67(9):1904-13. 30. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):85-95. 31. Cremers S, Farooki A. Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Ann N Y Acad Sci 2011;1218:80-7. 32. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(6):1167-73. 33. Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65(12):2397-410. 34. Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 2010;68(9):2241-7. 35. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22. 36. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009;67(1):159-61. 37. Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006;17(8):1336-7. 38. Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011;16(1):121-32. 39. Russell RG. Bisphosphonates: The first 40years. Bone 2011;49(1):2-19. 40. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136(8):1117-24. 41. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008;26(28):4634-8. 42. Katz J, Gong Y, Salmasinia D, Hou W, Burkley B, Ferreira P, et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. International journal of oral and maxillofacial surgery 2011;40(6):605-11. 43. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68(2):243-53. 44. Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST, Kolk A, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence - a multi-centre study. J Craniomaxillofac Surg 2011;39(4):272-7. 45. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009;67(4):850-5. 46. Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 2011;47(3):191-4. 47. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67(5):943-50. 48. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010;39(3):251-5. 49. Hohlweg-Majert B, Schmelzeisen R, Pfeiffer BM, Schneider E. Significance of osteoporosis in craniomaxillofacial surgery: a review of the literature. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006;17(2):167-79. 50. Ng MF. Cachexia - an intrinsic factor in wound healing. International wound journal 2010;7(2):107-13. 51. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011;49(1):56-65. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23442 | - |
dc.description.abstract | 目的: 雙磷酸鹽類藥物會抑制骨吸收,臨床上時常用來治療癌症骨轉移及骨質疏鬆症,近年來出現越來越多與此藥物相關的併發症案例:雙磷酸鹽類藥物相關顎骨壞死,嚴重影響病人的生活品質,本篇研究的目的在於探討與此相關的風險因子與預後因子,並驗證相關血清骨代謝生化指標是否可以作為雙磷酸鹽類藥物相關顎骨壞死發生及預後的預測工具。
病人與方法: 本研究自2003年至2011年收入157例在台大醫院口腔顎面外科確診為雙磷酸鹽類藥物相關顎骨壞死的病人,記錄系統性特徵、藥物資訊、可能的引發事件、臨床症狀、局部因子、治療方法及血清骨生化指標。接著以單變數、多變數分析方法及病例對照研究,找出可能影響發生雙磷酸鹽類藥物相關顎骨壞死的風險因子及預後因子。 結果: 157位病人中,有45位使用雙磷酸鹽類藥物治療癌症骨轉移,112位用來治療骨質疏鬆症,癌症組病人平均發生雙磷酸鹽類藥物相關顎骨壞死的時間較短(29.1個月,範圍6至84個月),骨鬆組病人為44.6個月(範圍6至180個月)。在發生雙磷酸鹽類藥物相關顎骨壞死癌症組病例對照研究中,經單變數分析,影響發生風險的因素有:多發性骨髓瘤(p=0.024)、使用雙磷酸鹽類藥物的時間長短(p=0.006)、合併使用類固醇(p=0.0011),以及進行牙科手術(p=0.012);經多變數分析,影響發生風險的因素有:使用雙磷酸鹽類藥物的時間長短(p=0.03)。在發生雙磷酸鹽類藥物相關顎骨壞死骨鬆組病例對照研究中,經單變數分析,影響發生風險的因素有:年齡(p=0.028)、使用BP藥物超過36個月(p<0.001);經多變數分析,影響發生風險的因素有:使用雙磷酸鹽類藥物超過36個月(p=0.004)。符合評估治療預後的107位病人中,有78位(72.9%)達到完全痊癒,平均治療天數為238.4天(範圍30至1506天);經單變數分析發現,女性(p=0.017)、使用雙磷酸鹽類藥物治療骨鬆(p<0.001)、使用福善美®(p<0.001)、未合併使用化療藥物(p=0.0013)、病灶數目較少(p=0.036)等因素會使預後較佳;病灶位於上顎區(p=0.018)、前牙區(p=0.0014),及自發性病灶(p=0.029)對於雙磷酸鹽類藥物相關顎骨壞死治療反應較迅速。血清骨生化指標對發生的風險與治療的預後,並沒有準確的預測價值。 結論: 本篇研究呈現台灣目前數量最大的病例系列,並找出影響雙磷酸鹽類藥物相關顎骨壞死發生與預後的風險因子,未來希望能針對這些風險因子及早介入預防,希望能減少雙磷酸鹽類藥物相關顎骨壞死之發生率,並縮短治療之病程。 | zh_TW |
dc.description.abstract | Purpose: Bisphosphonates (BPs) are bone-remodeling inhibitors that are commonly used to manage cancer bone metastases and osteoporosis. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a devastating side effect of BPs use. The purpose of this study was to identify factors that influence the occurrence and treatment outcomes of BRONJ, in addition, to determine whether related serum bone markers could be predictor for BRONJ.
Patients and Methods: This study evaluates 157 BRONJ cases diagnosed between 2003 and 2011 in Oral and Maxillofacial surgery department, National Taiwan University Hospital. Data on demographics, drugs use, possible trigger events, clinical symptoms, local factors, treatment methods, and serum bone markers are recorded. We use univariate analysis, multivariate analysis and a case-control study design to estimate possible risk factors and prognostic factors. Results: Of the 157 patients, 45 receive BP therapy for cancer and 112 for osteoporosis. The mean interval to development of BRONJ is shorter in the patients with cancer (29.1 months, range between 6 and 84 months) than patients with osteoporosis (44.6 months, range between 6 and 180 months). In BRONJ cancer case-control study, by univariate analysis, factors that increased the risk of BRONJ occurrence were multiple myeloma (p=0.024), duration of BPs use (p=0.006), combined steroid use (p=0.0011), dentoalveolar surgery (p=0.012). By multivariate analysis, the risk factor was duration of BPs ues (p=0.03). In BRONJ osteoporosis case-control study, by univariate analysis, factors that increased the risk of BRONJ occurrence were age (p=0.028), and BP therapy exceeded 36 months (p<0.001). By multivariate analysis, the risk factor was BP therapy exceeded 36 months (p=0.004). Of the 107 patients treated, 78 (72.9%) reach complete healing with a mean follow-up of 238.4 days (range between 30 and 1506 days). By univariate analysis, female (p=0.017), BP therapy for osteoporosis (p<0.001), alendronate (Fosamax®) use (p<0.001), no chemotherapy(p=0.0013), and fewer lesions (0.036) all seem to have better prognosis. Lesions located in maxilla (p=0.018) and anterior sextant (p=0.0014) and spontaneous lesions (p=0.029) respond faster to BRONJ treatment. However, serum bone markers are of little value to predict the occurrence and prognosis. Conclusion: We present the largest case series in Taiwan and identify the factors affecting the occurrence and treatment outcomes of BRONJ. Towards the factors, we hope for early intervention, reducing the incidence of BRONJ, and shortening the duration of treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:01:42Z (GMT). No. of bitstreams: 1 ntu-100-R98422030-1.pdf: 4230968 bytes, checksum: bfbfa04da85c194d44d486232454e549 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員會審定書 #
誌謝 i 中文摘要 ii 英文摘要 (ABSTRACT) iv 目錄 vi 圖目錄 xi 表目錄 xii Chapter 1 序論及文獻回顧 1 1.1 雙磷酸鹽類藥物 1 1.1.1 藥物使用 1 1.1.2 作用機轉 3 1.2 雙磷酸鹽類藥物與顎骨壞死 3 1.2.1 背景領域 3 1.2.2 定義與分級 4 1.2.3 成因 5 .1.2.3.1 正常骨代謝 5 .1.2.3.2 抑制骨代謝 6 .1.2.3.3 軟組織毒性 6 .1.2.3.4 抗血管生成 7 .1.2.3.5 微生物感染 7 .1.2.3.6 酸性環境 8 .1.2.3.7 微裂紋累積 8 1.2.4 流行病學 9 1.2.5 組織病理學特徵 10 1.2.6 危險因子 10 .1.2.6.1 系統性特徵因子 11 .1.2.6.2 藥物因子 11 .1.2.6.3 局部因子 11 .1.2.6.4 基因因子 12 1.2.7 治療策略 12 .1.2.7.1 保守性處理 13 .1.2.7.2 非手術性治療 14 .1.2.7.3 手術性治療 14 .1.2.7.3.1 局部手術 14 .1.2.7.3.2 大範圍切除手術 15 .1.2.7.4 輔助性療法 15 1.2.8 治療預後 15 1.3 檢驗血清骨代謝生化指標 16 1.3.1 C-terminal telopepetide(CTX) 17 1.3.2 Bone alkaline phosphatase(BALP) 18 1.3.3 Parathyroid hormone(PTH) 18 1.4 研究目的 18 Chapter 2 材料與方法 20 2.1 樣本選取 20 2.1.1 實驗組 20 2.1.2 對照組 21 2.2 研究設計 21 2.3 觀察項目 22 2.3.1 風險因子 22 .2.3.1.1 系統性特徵因子 22 .2.3.1.2 藥物因子 22 .2.3.1.3 局部因子 22 .2.3.1.4 抽血數值 22 2.3.2 病例對照研究 23 .2.3.2.1 癌症組血清骨生化指標數值基準 23 .2.3.2.2 癌症組 23 .2.3.2.3 骨質疏鬆組 23 2.3.3 影響預後的因子 24 .2.3.3.1 觀察因子 24 .2.3.3.2 分組 ………………………………………………………………...24 2.4 統計分析 25 2.4.1 分析方法 25 2.4.2 統計軟體 25 Chapter 3 實驗結果 26 3.1 風險因子 26 3.1.1 整體敘述性統計 26 3.1.2 癌症組病歷對照研究 27 .3.1.2.1 骨生化指標基準 27 .3.1.2.2 癌症組(單變數分析) 28 .3.1.2.3 癌症組(多變數分析) 29 .3.1.2.4 癌症組(有進行牙科手術) 29 3.1.3 骨質疏鬆組病歷對照研究 30 .3.1.3.1 骨鬆組(單變數分析) 30 .3.1.3.2 骨鬆組(多變數分析) 30 3.2 影響預後的因子 31 3.2.1 整體分析 31 3.2.2 癌症組 32 3.2.3 骨鬆組 33 3.2.4 整體已癒合病例評估 34 3.2.5 Kaplan-Meier分析 35 Chapter 4 討論 36 4.1 風險因子 37 4.1.1 系統性特徵因子 37 4.1.2 藥物相關因子 37 4.1.3 局部特徵因子 38 4.1.4 文獻回顧 38 4.2 病例對照研究 39 4.2.1 癌症組 39 4.2.2 骨鬆組 42 4.3 血清骨生化指標與停止使用雙磷酸鹽類藥物 44 4.3.1 風險評估 44 4.3.2 癌症組 45 4.3.3 骨鬆組 46 4.3.4 預後評估 47 4.4 預後因子 47 4.4.1 癌症組 50 4.4.2 骨鬆組 50 4.4.3 治療方法 51 4.4.4 癒合時間快慢 52 4.5 研究限制 55 Chapter 5 結論 57 5.1 BRONJ發生的風險因子 57 5.2 BRONJ治療的預後因子 57 5.3 血清骨生化指標 58 附圖 59 附表 67 參考文獻 109 | |
dc.language.iso | zh-TW | |
dc.title | 探討影響雙磷酸鹽類藥物相關顎骨壞死
發生的風險因子及治療的預後因子 | zh_TW |
dc.title | Factors affecting the occurrence and treatment outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 郭生興,高壽延 | |
dc.subject.keyword | 雙磷酸鹽類藥物,顎骨壞死,病例對照研究,風險因子,預後因子,血清骨生化指標, | zh_TW |
dc.subject.keyword | Bisphosphonates,Osteonecrosis of the jaw,Case-control study,Risk factor,Prognostic factor,Serum bone marker, | en |
dc.relation.page | 114 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2011-08-19 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 4.13 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。